• 23 December, 2025

Top 21-25

June 09, 2011 | Thursday | News


Siro Clinpharm
 SIRO Clinpharm Private Limited (SIRO), clocked an estimated sales revenue of 202 crore for FY 2010-11 when compared with 150 crore in 2009-10. During early 2011, the CRO announced the launch of its operations in Malaysia and also announced strategic alliances with CROs in South Korea and Taiwan in 2010. The company is in the process of evaluating Philippines and Thailand amongst other Asian countries for expanding its clinical operations. SIRO has strategic alliances and partnerships with several firms such as Clingene, Pfizer and with Fisher Clinical services. SIRO is a member of Bundesverband Medizinischer Auftragsinstitute, the German Federal Association of Contract Research Organizations. SIRO's laurels include, conducting over 130 clinical trails, recruiting over 20,000 clincial trial subjects, passing over 240 audits by sponsor QA teams and working on USFDA, EMEA, UK MHRA, Korean FDA WHO Health Canada and DCGI submissions.
Founder & Chairman
Dr Gautam Daftary
21
 Business: Offers clinical Trials services
Start-up Year: 1996
Address: DIL Premises, Ground Floor, Swami Vivekanand Rd, Near Tatwagyan Vidyapeeth, Ghodbhunder Rd, Thane (W)- 400607
Tel: +91-22-25848000
Fax: +91-22-25848475
Website: www.siroclinpharm.com
Revenue: 202 crore*


Cadila Healthcare
 Cadila Healthcare clocked biotech revenues worth 190.59 crore for FY 2010-11 as compared to the previous fiscal's revenue of 147.48 crore. Presently, the firm has 15 biosimilars and two novel products in its pipeline. The company is also looking at biobetters for the future growth and has dedicated 120 scientists for this purpose. Zydus Cadila acquired Italy-based, Etna Biotech, and the firm's Zydus Research Center (ZRC), has been working on strategic research collaboration with Prolong Pharmaceuticals, US, and Karo Bio, Sweden and Eli Lilly. Zydus Cadila has made swift progress on NME research and has 12 INDs in various stages of clinical trials and several more INDs in pre-clinical evaluation. The company also signed an agreement with Bayer HealthCare, in January 2011, to set up a joint venture company, Bayer Zydus Pharma, for the sales and marketing of pharmaceutical products in India.
CEO
Pankaj R Patel
22
 Business: Biologics and diagnostics
Start-up Year: 1995
Address: Cadila Healthcare Ltd., Zydus Tower, Satellite Cross Roads, Ahmedabad – 380015,Gujarat, INDIA
Tel: +91-79-26868100 Fax: +91-79-26862365
Website: www.zyduscadila.com
Revenue: 190.59 crore*


Tulip Group
 Tulip Group of companies clocked a total revenue of 185.63 crore for FY 2010-11 as against 182.48 crore in FY 2009-10. Revenues from domestic sales for FY 2010-11 were 128.23 crore, while the firm reported exports worth 57.40 crore. During the fiscal, the company made investments worth 89.25 crore, including 1.67 crore in R&D, 20.25 crore in infrastructure and 30.01 crore on manpower. The group has on its rolls a total staff of 1,033 people and consists of several individual companies such as Tulip Diagnostics, Microxpress, Orchid Biomedical Systems, Qualpro Diagnostics, Zephyr Biomedicals, Coral Clinical Systems, BioShields, Tulip Marketing, Crest Biosystems and Lilac Medicare. It also has marketing alliances with companies like Monobind, US; Orgentec, Germany and TOSOH, Japan. The company's products are distributed across 55 countries, it has a sales team of 325 personnel, has a customer base of over 15,000 and has 300 distributors.
CEO
Dr Dilip Tripathi
23
 Business: Manufacture and marketing of in vitro Diagnostic reagents and kits
Start-up Year: 1988
Address: Gitanjali, Tulip Block, Dr Antonio Do Rego Bagh, Alto Santacruz, Bambolim Complex Post Office, Goa - 403 202, INDIA
Tel: (0832) 2458546-51 Fax: (0832) 2458544
Website: www.tulipgroup.com
Revenue: 185.63 crore*


GlaxoSmithKline Pharmaceuticals
 GlaxoSmithKline (GSK) Pharmaceuticals, an affiliate of GlaxoSmithKline Biologicals, headquartered in Rixensart, Belgium, clocked an estimated sales of 163 crore in 2010-11 as compared to 123.34 crore in 2009-10. Today, GSK has a market share of 20 percent in the total Indian private vaccine segment. Vaccines contributed to nine to 10 percent of its total sales in the current year and in the coming years the company is looking at a growth of around 15 percent from its vaccines product portfolio. GSK India has 14 vaccines in its product basket, including Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed) and Cervarix, (human papillomavirus vaccine (types 16 and 18)) among others. The company's vaccine facility in Nasik, Maharashtra, is expected to witness an overhaul of 100 crore in the next three years. The Nashik facility also accounts for half of GSK's annual manufacturing capacity for its lymphatic filariasis (LF) programme.
CEO
Dr Hasit Joshipura
24
 Business: Sales of vaccines and biologicals
Start-up Year: 2001
Address: Dr Annie Besant Road, Worli, Mumbai-40030
Tel: +91-22-24959205 Fax: +91-22-24914863
Website: www.gsk-india.com
Revenue: 163 crore*


Monsanto India
Monsanto India clocked revenue sales of 161 crore in FY 2010-11 as against 142.4 crore in 2009-10. Monsanto has been selling Bt cotton hybrids in India for the last five years under Monsanto Holdings Private Limited (MHPL). MHPL is focused on marketing Paras cotton hybrid seeds with Bollgard and Bollgard Bt cotton technologies and Seminis vegetable hybrid seeds. It was estimated that the company sold about 18 lakh packets of Bollgard during the 2010 kharif season, which is an increase of two lakh as comapred to the same period in the last year. Monsanto has launched Project SHARE (Sustainable Harvest Agriculture, Resources, Environment), a sustainable yield initiative with an NGO called the Indian Society of Agribusiness Professionals (ISAP), to improve the socio-economic conditions of 10,000 small-marginal corn and cotton farmers in 1,100 villages in Andhra Pradesh, Maharashtra and Rajasthan within four years.
Managing Director
Mr Amitabh Jaipuria
25
 Business: Production and sale of herbicides, hybrid seeds and pesticides
Start-up Year: 1949
Address: Ahura Centre, 5th Floor, 96, Mahakali Caves Road, Andheri (East), Mumbai -400 093
Tel: +91-22-28246450 Fax: +91-22-26902121
Website: www.monsantoindia.com
Revenue: 161 crore*

Comments

× Your session has expired. Please click here to Sign-in or Sign-up
New User? Create Account

Trending Topics

Most Read

Survey Box

Is 2026 set to witness AI-driven disease surveillance and early diagnosis?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy